Presented By: Mitchell Brin, MD, Eman Elkadry, MD, and Vincent Lucente, MD

Hear from three experts in a roundtable discussion to learn about the innovation and proven science of a third-line overactive bladder treatment, ways you can create a patient-centric experience, and their personal experience with patients.

1. Learn about the origins and innovation of a third-line therapy
2. Understand the importance of advancing appropriate OAB patients beyond oral medications
3. Review the clinical data, procedure, and ways to improve patient comfort for an OAB treatment
4. Know how to access training and support from Allergan, an Abbvie company

Mitchell Brin, MD Senior Vice President, Chief Scientific Officer, BOTOX® and Neurotoxins, Allergan, an AbbVie company
Dr. Brin is Senior Vice President Global Development & Chief Scientific Officer for BOTOX® and Neurotoxins and joined Allergan, an Abbvie company in 2001. He continues to publish actively and is Clinical Professor of Neurology at the University of California Irvine, where he evaluates and treats patients.






Eman Elkadry, MD Boston Urogynecology Associates Cambridge, MA
Dr. Elkadry is a urogynecologist and board certified in Female Pelvic Medicine and Reconstructive Surgery based out of Boston, MA. She currently practices at Boston Urogynecology Associates and trains fellows at Mount Auburn Hospital.







Vincent Lucente, MD Institute of Female Pelvic Medicine & Reconstructive Surgery Allentown, PA
Dr. Lucente is a urogynecologist and board certified in Female Pelvic Medicine and Reconstructive Surgery and based in Allentown, PA. He is the medical director of the Institute for Female Pelvic Medicine and Reconstructive Surgery. Dr. Lucente is also Chief, Gynecology, St. Luke's University Health Network and Clinical Professor of Obstetrics and Gynecology, Temple University College of Medicine.